TR201110525A2 - Kemik hastalıklarının tedavisinde kullanılmak üzere suda çözünebilir farmasötik bileşimler. - Google Patents

Kemik hastalıklarının tedavisinde kullanılmak üzere suda çözünebilir farmasötik bileşimler.

Info

Publication number
TR201110525A2
TR201110525A2 TR2011/10525A TR201110525A TR201110525A2 TR 201110525 A2 TR201110525 A2 TR 201110525A2 TR 2011/10525 A TR2011/10525 A TR 2011/10525A TR 201110525 A TR201110525 A TR 201110525A TR 201110525 A2 TR201110525 A2 TR 201110525A2
Authority
TR
Turkey
Prior art keywords
treatment
water
pharmaceutical compositions
bone diseases
soluble pharmaceutical
Prior art date
Application number
TR2011/10525A
Other languages
English (en)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2011/00151A external-priority patent/TR201100151A2/tr
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2011/10525A priority Critical patent/TR201110525A2/tr
Priority to PCT/TR2012/000007 priority patent/WO2012093976A1/en
Publication of TR201110525A2 publication Critical patent/TR201110525A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Mevcut buluş hiperkalsemi, osteoporoz, tümör osteolizi, malin hiperkalsemi, metastatik kemik hastalığı, periprostatik kemik kaybı, Paget hastalığı gibi kemik hastalıklarının tedavisinde ve/ veya önlenmesinde kullanılmak üzere suda çözünebilir formülasyonlar ve bunların üretim yöntemleri ile ilgilidir.
TR2011/10525A 2011-01-06 2011-10-24 Kemik hastalıklarının tedavisinde kullanılmak üzere suda çözünebilir farmasötik bileşimler. TR201110525A2 (tr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2011/10525A TR201110525A2 (tr) 2011-01-06 2011-10-24 Kemik hastalıklarının tedavisinde kullanılmak üzere suda çözünebilir farmasötik bileşimler.
PCT/TR2012/000007 WO2012093976A1 (en) 2011-01-06 2012-01-06 A composition comprising ibandronate at least 50 % of a filling agent and a sweetener

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2011/00151A TR201100151A2 (tr) 2011-01-06 2011-01-06 İbandronate formülasyonu.
TR2011/10525A TR201110525A2 (tr) 2011-01-06 2011-10-24 Kemik hastalıklarının tedavisinde kullanılmak üzere suda çözünebilir farmasötik bileşimler.

Publications (1)

Publication Number Publication Date
TR201110525A2 true TR201110525A2 (tr) 2012-07-23

Family

ID=45722687

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2011/10525A TR201110525A2 (tr) 2011-01-06 2011-10-24 Kemik hastalıklarının tedavisinde kullanılmak üzere suda çözünebilir farmasötik bileşimler.

Country Status (2)

Country Link
TR (1) TR201110525A2 (tr)
WO (1) WO2012093976A1 (tr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030177A2 (en) * 2003-09-29 2005-04-07 Cipla Limited Pharmaceutical formulation with improved stability
EP2416756A2 (en) * 2009-04-10 2012-02-15 Mahmut Bilgic Stable pharmaceutical compositions with high bioavailibility

Also Published As

Publication number Publication date
WO2012093976A1 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
WO2013009701A3 (en) Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
MX343687B (es) Compuestos sulfonamida tricíclica y métodos para su fabricación y uso.
MX347471B (es) Vacunas que comprenden colesterol y cpg como moleculas portadoras-adyuvantes unicas.
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
IN2012DN02736A (tr)
MX339201B (es) Compuestos de sulfonamida y métodos para elaborarlos y usarlos.
GB201209613D0 (en) New compounds
MX343688B (es) Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
MX2015006152A (es) Compuestos de aminopirimidina como inhibidores de mutantes de egfr que contienen t7 9 0m.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
MD4733B1 (ro) Anticorpi anti-TIGIT
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
MX341395B (es) Compuestos (lipopeptidos basados en cisteina) y composiciones como agonistas de tlr2 usados para el tratamiento de infecciones, inflamaciones, enfermedades respiratorias, etc.
MX2014008706A (es) Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
MX354481B (es) Anticuerpos dkk1 y métodos de uso.
MY186106A (en) Diagnosis, prevention and treatment of diseases of the joint
MX394137B (es) Compuestos y composiciones novedosas para atacar las células madre del cáncer.
MX2013001677A (es) Formulaciones estables de linaclotida.
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
MY196771A (en) Vesicles which include epidermal growth factor and compositions that contain same
MX357166B (es) Anticuerpos que se unen a notum pectinacetilesterasa.
NZ708821A (en) Lfa-1 inhibitor formulations
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.